Under NCCN guidelines, adjuvant endocrine therapy is recommended for hormone receptor positive BC, including selective estrogen receptor modulator (SERM), selective estrogen receptor downregulator (SERD), aromatase inhibitor (AI), and GnHa. The gene discussed is NR4A1; the disease is breast cancer.